Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints
EV Minikel, HT Zhao, J Le, J O'Moore… - Nucleic acids …, 2020 - academic.oup.com
Lowering of prion protein (PrP) expression in the brain is a genetically validated therapeutic
hypothesis in prion disease. We recently showed that antisense oligonucleotide (ASO)-…
hypothesis in prion disease. We recently showed that antisense oligonucleotide (ASO)-…
Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy
DL Graham, AJ Gray, JA Joyce, D Yu, J O'Moore… - …, 2014 - Elsevier
Neurofibrillary tangles (NFT), mainly consisting of fibrillar aggregates of hyperphosphorylated
tau, are a defining pathological feature of Alzheimer's Disease and other tauopathies. …
tau, are a defining pathological feature of Alzheimer's Disease and other tauopathies. …
The claw paw mutation reveals a role for Lgi4 in peripheral nerve development
…, H Shearin, J Pennington, J O'Moore… - Nature …, 2006 - nature.com
Peripheral nerve development results from multiple cellular interactions between axons,
Schwann cells and the surrounding mesenchymal tissue. The delayed axonal sorting and …
Schwann cells and the surrounding mesenchymal tissue. The delayed axonal sorting and …
[HTML][HTML] Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS
…, AG Reidenbach, JE Gentile, E Kuhn, J O'Moore… - JCI insight, 2022 - ncbi.nlm.nih.gov
Prion protein (PrP) concentration controls the kinetics of prion replication and is a genetically
and pharmacologically validated therapeutic target for prion disease. In order to evaluate …
and pharmacologically validated therapeutic target for prion disease. In order to evaluate …
Therapeutic trial of anle138b in mouse models of genetic prion disease
SM Vallabh, D Zou, R Pitstick, J O'Moore… - Journal of …, 2023 - Am Soc Microbiol
Phenotypic screening has yielded small-molecule inhibitors of prion replication that are
effective in vivo against certain prion strains but not others. Here, we sought to test the small …
effective in vivo against certain prion strains but not others. Here, we sought to test the small …
[HTML][HTML] Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400
…, S Ousson, M Neny, D Beher, G Carlson, J O'Moore… - FEBS letters, 2013 - Elsevier
Aggregation of tau into paired helical filaments is a pathological process leading to neurotoxicity
in Alzheimer’s disease and other tauopathies. Tau is posttranslationally modified by O-…
in Alzheimer’s disease and other tauopathies. Tau is posttranslationally modified by O-…
PrP concentration in the central nervous system: regional variability, genotypic effects, and pharmacodynamic impact
…, AG Reidenbach, JE Gentile, E Kuhn, J O'Moore… - medRxiv, 2021 - medrxiv.org
Prion protein (PrP) concentration controls the kinetics of prion replication and is a genetically
and pharmacologically validated therapeutic target for prion disease. In order to evaluate …
and pharmacologically validated therapeutic target for prion disease. In order to evaluate …
[HTML][HTML] Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 …
Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). …
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). …
Fluid restriction during running increases GI permeability
The purpose of this study was to determine gastrointestinal (GI) permeability during prolonged
treadmill running (60 min at 70% V· O 2max) with and without fluid intake (3 ml/kg body …
treadmill running (60 min at 70% V· O 2max) with and without fluid intake (3 ml/kg body …
[PDF][PDF] Regional variability, genotypic effects, and pharmacodynamic impact on prion protein concentration in the central nervous system
…, AG Reidenbach, JE Gentile, E Kuhn, J O'Moore… - prionalliance.org
Reliable and scalable quantification of prion protein (PrP) is vital to the development of PrP-lowering
drugs for prion disease. Here we develop a plate-based immunoassay reactive for …
drugs for prion disease. Here we develop a plate-based immunoassay reactive for …